Anti-Psoriatic Therapy Recovers High-Density Lipoprotein Composition and Function  by Holzer, Michael et al.
Anti-Psoriatic Therapy Recovers High-Density
Lipoprotein Composition and Function
Michael Holzer1, Peter Wolf2, Martin Inzinger2, Markus Trieb1, Sanja Curcic1, Lisa Pasterk1, Wolfgang Weger2,
Akos Heinemann1 and Gunther Marsche1
Psoriasis is a chronic inflammatory disorder associated with increased cardiovascular mortality. Psoriasis affects
high-density lipoprotein (HDL) composition, generating dysfunctional HDL particles. However, data regarding the
impact of anti-psoriatic therapy on HDL composition and function are not available. HDL was isolated from 15
psoriatic patients at baseline and after effective topical and/or systemic anti-psoriatic therapy and from 15 age-
and sex-matched healthy controls. HDL from psoriatic patients showed a significantly impaired capability to
mobilize cholesterol from macrophages (6.4 vs. 8.0% [3H]cholesterol efflux, Po0.001), low paraoxonase (217 vs.
350mM 1minute 1mg 1 protein, P¼ 0.011) and increased Lp-PLA2 activities (19.9 vs. 12.1nM 1minute 1mg 1
protein, P¼ 0.028). Of particular interest, the anti-psoriatic therapy significantly improved serum lecithin-
cholesterol acyltransferase activity and decreased total serum lipolytic activity but did not affect serum levels
of HDL-cholesterol. Most importantly, these changes were associated with a significantly improved HDL-
cholesterol efflux capability. Our results provide evidence that effective anti-psoriatic therapy recovers HDL
composition and function, independent of serum HDL-cholesterol levels, and support to the emerging concept
that HDL function may be a better marker of cardiovascular risk than HDL-cholesterol levels.
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INTRODUCTION
Epidemiological and clinical studies have consistently shown
that psoriasis is associated with an increased cardiovascular
risk (Mehta et al., 2010, Armstrong et al., 2013). Psoriasis, a
widespread chronic inflammatory disease, affects about
2–3% of the population. Although generally characterized
by typical lesions on the skin of the trunk, extremities, and
scalp, psoriasis also affects the entire organism by maintaining
a low-grade inflammatory status. Traditional risk factors
for cardiovascular disease, such as hypertension, elevated
C-reactive protein, and obesity, are more frequent in psoriatic
patients than in the normal population (Neimann et al., 2006,
Kaplan, 2008). Patients with psoriasis are more likely to have
a deteriorated lipid profile, with higher triglyceride levels
and significantly decreased high-density lipoprotein (HDL)-
cholesterol (Rocha-Pereira et al., 2001).
It is thought that HDL protects against cardiovascular
disease by removing cholesterol from artery wall macrophages
in a process called reverse cholesterol transport. In addition,
HDL exerts additional anti-atherogenic effects, such as
anti-oxidative activities (Kontush and Chapman, 2010).
Despite the clear epidemiological evidence that plasma
levels of HDL-cholesterol are inverse and independent
predictors of cardiovascular disease risk, genetic studies
have yielded inconsistent data (Voight et al., 2012).
Moreover, raising HDL-cholesterol by the cholesteryl-ester
transfer protein (CETP) inhibitors torcetrapib and dalcetrapib
did not translate into cardiovascular protection (Landmesser
et al., 2012), supporting to the emerging concept that
HDL function is a better marker than HDL-cholesterol
levels. In line with this assumption, a recent study clearly
showed that HDL-cholesterol efflux capacity, independently
of HDL-cholesterol levels, was inversely associated with the
risk of coronary artery disease (Khera et al., 2011). Given that
inflammation alters the HDL particles in terms of structure,
size, composition, and metabolism, it is becoming
increasingly apparent that direct measures of HDL function
are needed rather than relying on surrogate markers, such as
the concentration of HDL-cholesterol (Marsche et al., 2013,
Shah et al., 2013, Triolo et al., 2013). Recent work from our
group has shown that psoriasis alters HDL composition and
function (Holzer et al., 2012), reflecting a shift to a pro-
atherogenic profile, associated with an impaired cholesterol
efflux capacity of HDL.
In the present study, we investigated whether anti-psoriatic
therapy affects HDL function. Our study included paired
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measurements of patients with disease and multiple measures
of HDL function and composition. For that purpose, we
isolated HDL of healthy subjects and psoriasis patients before
and after anti-psoriatic therapy and assessed HDL func-
tionality.
RESULTS
Anti-psoriatic therapy does not alter blood lipid levels
HDL was isolated from 15 psoriasis patients at baseline and
after anti-psoriatic therapy and from 15 age- and sex-matched
controls. Clinical characteristics, medical history, and indivi-
dual treatments plans are given in Table 1, Supplementary
Tables S1 and S2 online. Evaluation of the psoriasis area and
severity index (PASI) clearly indicated a significant improve-
ment in diseases severity over the treatment period (Table 1,
Figure 1a, Supplementary Table S2 online), without affecting
body weight of patients. Circulating C-reactive protein levels
in the treatment group tended to decrease but did not reach
statistical significance (Table 1). Anti-psoriatic therapy did not
alter blood lipid levels in the treatment group and HDL-
cholesterol levels remained significantly lower than compared
with the control group (Table 1).
Effect of anti-psoriatic therapy on HDL-mediated cholesterol
efflux
To compare the functionality of HDL particles before and after
anti-psoriatic therapy, we measured HDL-mediated choles-
terol efflux for each subject using RAW264.7 macrophages.
In line with our previous study (Holzer et al., 2012), we
observed a reduction of cholesterol efflux capacity of
HDL from psoriatic patients when compared with control sub-
jects. Most importantly, cholesterol efflux capability of HDL
improved significantly after anti-psoriatic therapy (Figure 1b
and d) and correlated negatively with the PASI score
(Figure 1e). When baseline and therapy measurements were
analyzed separately, we observed that at baseline a borderline
correlation between cholesterol efflux and PASI was present
(r¼ 0.483, P¼0.068), whereas after treatment the correla-
tion was significant (r¼  0.621, P¼ 0.013). Total cholesterol
and C-reactive protein tended to decrease in patients after
anti-psoriatic therapy. However, the correlation between
cholesterol efflux and PASI remained significant after adjusting
for total cholesterol and C-reactive protein.
To validate results obtained with mouse RAW264.7 macro-
phages, cholesterol efflux experiments were performed using
human lipid-laden THP1 macrophages. Experiments in
human THP1 macrophages revealed comparable results
(Supplementary Figure S1a and b online), and a signifi-
cant correlation between efflux measures in RAW264.7 and
THP1 macrophages was present (Supplementary Figure S1c
online).
Anti-psoriatic therapy may affect different HDL subpopula-
tions. During the ultracentrifugation procedure to isolate HDL,
a part of lipid-poor pre-beta-1 particles strips off. Pre-beta-1
particles are preferred acceptors for ABCA1-mediated choles-
terol efflux (de la Llera-Moya et al., 2010). To gain further
insights whether anti-psoriatic therapy also affects pre-beta-1
particles, cholesterol efflux capability of apolipoprotein B
(apoB)-depleted serum (containing all HDL subpopulations)
was assessed using ABCA1-upregulated RAW264.7 macro-
phages. In this particular assay, pre-beta-1 particles are the
main driver of ABCA1-mediated cholesterol efflux even in the
presence of all other HDL subpopulations (Asztalos et al.,
2005). In good agreement with a recent study (Mehta et al.,
2012), we observed that cholesterol efflux capacity of apoB-
depleted serum of psoriatic patients was significantly lower
(Figure 1c). However, in contrast to efflux experiments
performed with isolated HDL, we did not observe an improve-
ment of cholesterol efflux capability of apoB-depleted sera
after anti-psoriatic therapy (Figure 1c), and cholesterol efflux
capability of apoB-depleted sera did not correlate with PASI
(Figure 1f).
Table 1. Clinical characteristics of study subjects
Psoriasis
Controls Baseline After anti-psoriatic treatment
n 15 15 15
Age (years) 43 (35.0–60.1) 49.7 (42.1–65.4) 50.7 (43.3–67.3)
Male/female 10/5 12/3 12/3
PASI — 16.6 (10.7–21.3) 6 (2.4–11.8)w
CRP (nmol l1) 2.9 (0–3) 59 (5–125) 41 (4–101)
Total cholesterol (mmol l 1) 5.2 (4.4–5.9) 5.3 (4.1–5.7) 4.8 (4.0–5.5)
Triglycerides (mmol l 1) 1.3 (0.9–2.2) 1.8 (0.8–2.1) 1.7 (0.8–2.8)
HDL-cholesterol (mmol l1) 1.7 (1.3–2.0) 1.2 (0.9–1.4)* 1.1 (0.9–1.2)*
LDL-cholesterol (mmol l1) 3.0 (2.3–3.5) 3.1 (2.1–4.1) 3.0 (2.1–3.8)
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PASI, psoriasis area and severity index.
Results are given as medians with interquartile range.
*Po0.05 vs. control.
wPo0.05 vs. baseline.
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Anti-psoriatic therapy alters HDL composition
We next analyzed the phospholipid content of isolated
HDL, given that the phospholipid content is critical for choles-
terol efflux capacity of mature HDL (Sankaranarayanan et al.,
2009, Holzer et al., 2011a). Of note, anti-psoriatic therapy
increased HDL-phospholipid content to levels observed in
HDL of the control group (Figure 2a). The HDL-phospholipid
content significantly correlated with cholesterol efflux capa-
cities of HDL within the control and the psoriasis groups
(Figure 2b).
Anti-psoriatic therapy increases lecithin-cholesterol
acyltransferase (LCAT) activity and reduces total serum
lipolytic activity
Prompted by the observation that the anti-psoriatic therapy
is associated with compositional alterations of HDL, we
assessed whether anti-psoriatic therapy affects phospho-
lipid transfer protein (PLTP), LCAT, CETP, and total lipase
activities of sera to assess the underlying mechanism(s).
Interestingly, we observed that anti-psoriatic therapy did
not alter serum PLTP (Figure 3a) and CETP (Figure 3b)
activities, whereas LCAT activity was significantly increased
(Figure 3c). LCAT converts free cholesterol into cholesteryl
ester, making the newly synthesized HDL spherical.
In contrast to LCAT activity, the serum lipolytic activity in
patients after anti-psoriatic therapy was significantly decreased
(Figure 3d). In agreement with the increased LCAT activity
and decreased serum lipolytic activity, an increased HDL
subpopulation with large particle size (12–16 nm) was
observed by native gel electrophoresis (Figure 3e).
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Figure 1. Psoriasis impairs cholesterol efflux capability of HDL. (a) Psoriasis area and severity index (PASI) score at baseline and after anti-psoriatic therapy.
(b) High-density lipoprotein (HDL; 50mg ml1 protein) isolated from 15 control subjects and 15 psoriatic patients at baseline and after anti-psoriatic therapy
were examined for its ability to induce [3H]cholesterol efflux from RAW264.7 macrophages. Cholesterol efflux is expressed as radioactivity in the supernatant
relative to total radioactivity. Values shown represent means of two individual experiments performed in duplicate. (c) Apolipoprotein B (ApoB)-depleted serum
(2.8%) was examined for its ability to induce [3H]cholesterol efflux from cAMP-stimulated RAW264.7 macrophages. Values shown represent means of two
individual experiments performed in duplicate. The Spearman correlation coefficient is noted. (d) HDL-mediated [3H]cholesterol efflux from RAW264.7
macrophages at baseline and after anti-psoriatic therapy. (e) Correlation between PASI and [3H]cholesterol efflux induced by HDL. (f) Correlation between
PASI and apoB-depleted serum mediated [3H]cholesterol efflux. The Spearman correlation coefficients are noted with its significance level.
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Figure 2. High-density lipoprotein-phospholipid (HDL-PL) content
correlates with the cholesterol efflux capability of HDL. (a) Quantification
of phospholipid content in isolated HDL from healthy controls and
psoriasis patients at baseline and after anti-psoriatic therapy. Results
represent duplicate measurements of three independent experiments.
(b) Correlation between HDL-mediated [3H]-cholesterol efflux from
macrophages and the HDL-PL content. Spearman correlation coefficients
are noted for each plot.
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Effects of anti-psoriatic therapy on paraoxonase and
lipoprotein-associated phospholipase A2 (Lp-PLA2) activities
Paraoxonase, an important HDL-associated enzyme, has
been implicated in anti-oxidant and anti-inflammatory func-
tions (Mackness and Mackness, 2010, Aviram, 2011), and its
activity has been related to cardiovascular risk (Bhattacharyya
et al., 2008). We observed that paraoxonase activity of
HDL from psoriasis patients was significantly lower, when
compared with controls. Another HDL-associated enzyme,
Lp-PLA2, has recently been associated with an enhanced risk
of coronary artery disease (Rosenson and Stafforini, 2012).
Lp-PLA2 activity is significantly increased in psoriasis patients
and patients suffering from end-stage renal disease (Holzer
et al., 2011a, 2012). In line with our previous study (Holzer
et al., 2012), we observed that the activity of Lp-PLA2 was
significantly increased in the psoriasis group. Interestingly,
anti-psoriatic therapy tended to recover HDL-paraoxonase and
Lp-PLA2 activities (Figure 4a and b).
HDL exhibits unique anti-oxidative activities (Kontush and
Chapman, 2010). To assess the anti-oxidative activity of HDL,
we monitored the ability of HDL to inhibit oxidation of the
fluorescent dye dihydrorhodamine (DHR). We observed that
HDL from controls and psoriasis patients is similarly potent in
inhibiting radical-induced oxidation of dihydrorhodamine,
suggesting that anti-oxidant activity of psoriatic HDL is not
significantly altered (Figure 4c).
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Figure 3. Anti-psoriatic therapy reduces serum lipase activity. Quantification
of (a) phospholipid transfer protein (PLTP), (b) cholesteryl-ester transfer protein
(CETP), (c) lecithin-cholesterol acyltransferase (LCAT), and (d) serum total
lipolytic (lipase) activities. Enzymatic activities where measured in serum of
psoriasis patients at baseline and after anti-psoriatic therapy with commercial
available kits as described in the Materials and Methods section. Results
represent measurements of three independent experiments. (e) Pooled high-
density lipoprotein samples were separated by native gel electrophoresis and
stained with Coomassie Brillant Blue G-250. A gel image was analyzed with
ImageJ software to obtain an intensity plot. Standard proteins are indicated
as dotted lines with their size in nm.
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Figure 4. Anti-psoriatic therapy increases paraoxonase activity and reduces
lipoprotein-associated phospholipase A2 (Lp-PLA2) activity on isolated
high-density lipoprotein (HDL). (a, b) Activity of HDL-associated paraoxonase
was measured using paraoxon as substrate. (c, d) Lipoprotein-associated
phospholipase A2 (Lp-PLA2) activity of HDL was measured using 2-thio PAF
as substrate. Paraoxonase and Lp-PLA2 activities of HDL were calculated
from the slopes of the kinetic chart of three independent experiments.
(e, f) The anti-oxidative activity of HDL was determined by inhibition of AAPH-
initiated oxidation of the fluorescent dye dihydrorhodamine (DHR). Incubation
of DHR in presence of HDL from healthy subjects (control) or psoriasis patients
(psoriasis) led to a reduction in the oxidation of DHR. Results represent
measurements of three independent experiments.
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DISCUSSION
Several clinical studies have shown that psoriatic patients face
an increased burden of cardiovascular disease (Mehta et al.,
2010, Armstrong et al., 2013), which cannot fully be
explained by traditional risk factors (Neimann et al., 2006).
Recent work from our group and others has shown that
psoriasis alters HDL composition and function (Holzer et al.,
2012), reflecting a shift to a pro-atherogenic profile, associated
with an impaired cholesterol efflux capacity of isolated HDL.
The data presented here describe the previously unreported
observation that an effective anti-psoriatic therapy, as shown
by a significant improvement in PASI score, markedly recovers
HDL function.
We performed cholesterol efflux experiments with isolated
HDL in two macrophage cell lines (RAW264.7, THP1) and
observed that anti-psoriatic therapy significantly improved
HDL-cholesterol efflux capacity. Notably, anti-psoriatic ther-
apy showed no effect on HDL or low-density lipoprotein
(LDL)-cholesterol levels, providing evidence that HDL func-
tion is not adequately reflected by HDL-cholesterol levels.
Efflux of cholesterol is regulated by the phospholipid content
and size of larger, spherical HDL particles that are the
preferred acceptors of the cholesterol released from cells by
ABCG1 and scavenger receptor BI (Yancey et al., 2000,
Sankaranarayanan et al., 2009). Interestingly, anti-psoriatic
therapy increased the phospholipid content of HDL that
correlated significantly with the cholesterol efflux capability,
providing support to the concept that the phospholipid content
is critical for cholesterol efflux capacity of mature HDL
(Sankaranarayanan et al., 2009, Holzer et al., 2011a).
Interestingly, we observed that anti-psoriatic therapy was
associated with increased LCAT activity and reduced serum
lipolytic activity, whereas CETP and PLTP activities were not
altered. These data suggest that activities of LCAT and serum
lipases are modulated by low-grade inflammation and are
recovered by anti-psoriatic therapy. As a consequence of anti-
psoriatic therapy–associated alterations in LCAT and total
serum lipolytic activities, a HDL subpopulation with increased
particle size was observed that likely contributes to the
increased HDL-cholesterol efflux capacity.
A recent study has provided compelling evidence that
cholesterol efflux of ABCA1-upregulated macrophages pro-
moted by apoB-depleted serum is inversely associated with
the risk of coronary artery disease (Khera et al., 2011). In line
with a recent report (Mehta et al., 2012), we observed that
cholesterol efflux capacity of apoB-depleted serum is reduced
in psoriasis patients using this particular cholesterol efflux
assay. Interestingly, anti-psoriatic therapy did not improve
cholesterol efflux capability of apoB-depleted serum. It has to
be noted that cholesterol efflux to apoB-depleted serum during
the reported cholesterol efflux assay mainly reflects the
cholesterol acceptor activity of the lipid-poor apoA-I pool
via ABCA1. Mature HDL particles serve as only a minor
acceptor (E40%) of radiolabeled cholesterol within the apoB-
depleted serum (Li et al., 2013). Enhanced LCAT activity is
associated with the formation of large HDL particles, whereas
LCAT deficiency leads to accumulation of nascent HDL due to
impaired maturation of HDL particles (Kunnen and Van Eck,
2012). Therefore, it might be assumed that anti-psoriatic
therapy–associated increases in LCAT activity, on the one
hand, forms large HDL particles with increased cholesterol
acceptor capability but, on the other hand, reduces lipid-poor
pre-beta-1 HDL levels, resulting in unaltered cholesterol
acceptor capability of apoB-depleted serum. In agreement
with that assumption is the fact that sera of carriers of LCAT
gene mutations have unaltered capacities to promote choles-
terol efflux (Calabresi et al., 2009), because efflux driven by
low levels of large, spherical HDL is compensated by
increased efflux-driven lipid-poor pre-beta-1 HDL (Kunnen
and Van Eck, 2012). Therefore, it has to be noted that our
finding of a recovery of HDL-cholesterol-efflux capacity by
anti-psoriatic therapy reflects alterations in the composition
and function of mature HDL.
Other proteins such as paraoxonase that co-transport with
HDL in serum are well known to have anti-atherogenic
properties. In contrast to our previous study (Holzer et al.,
2012), we here observed that paraoxonase activity in psoriasis
patients was significantly lower when compared with healthy
controls. This apparently contrasting finding may be explained
by a higher mean PASI score of the psoriatic patients of our
present study (17.6 vs. 11.4), suggesting that a higher
inflammatory state is linked to lower paraoxonase activity,
as suggested by others (Toker et al., 2009). In line with our
previous study (Holzer et al., 2012), we observed that the
activity of HDL-associated Lp-PLA2 was significantly
increased in the psoriasis group. Interestingly, anti-psoriatic
therapy tended to recover HDL paraoxonase and Lp-PLA2
activities, suggesting that other potential anti-atherogenic
properties of HDL are recovered, at least in part.
Interestingly, we observed that control HDL and HDL from
psoriatic patients at baseline and after therapy inhibited DHR
oxidation to a similar extent although paraoxonase activity
was significantly altered. Besides HDL-associated paraoxo-
nase, Lp-PLA2, LCAT, and plasmalogens may significantly
contribute to the anti-oxidative activity of HDL. Given that
Lp-PLA2 activity was significantly increased in psoriatic HDL
(and LCAT activity after anti-psoriatic therapy), low paraoxo-
nase activity of psoriatic HDL might be compensated by
increased Lp-PLA2 and LCAT activities. Interestingly, a recent
study provided evidence that paraoxonase prevents LCAT
inactivation (Hine et al., 2012), hence improvement of
paraoxonase activity through anti-psoriatic therapy might
trigger increased LCAT activity, at least in part. However,
much more research into the HDL anti-oxidant system needs
to be done to dissect the exact mechanism(s) at work.
To provide indications about the efficacy of different anti-
psoriatic therapies on PASI and HDL parameters, we provide
data of individual patients and the effectiveness of their
therapy (Supplementary Table S3 online). These data suggest
that all therapies are effective in reducing PASI, whereby
differences in HDL parameters seemed to be most pronounced
in patients receiving systemic therapies (tumor necrosis factor
inhibition, anti-interleukin-23, and other systemic therapies)
(Supplementary Table S3 online).
Several study limitations have to be noted. The lack of a
control arm consisting of patients with psoriasis who do not
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receive anti-psoriatic therapy over the same time period does
not allow proving a cause-and-effect relationship within this
explorative study. Our study is limited by the correlative
nature, not permitting causal inference. Moreover, due to
the small sample size, we cannot exclude the possibility
that potential significant differences are missed. Therefore,
further studies in larger cohorts are warranted to confirm our
results.
In summary, our results provide previously unreported
evidence that effective anti-psoriatic therapy is able to
improve HDL function. Of particular interest in this regard
is the recent observation that anti-inflammatory therapies
of psoriasis patients improve cardiovascular outcome
(Ahlehoff et al., 2013). Hence, anti-psoriatic therapy–associ-
ated improvements of HDL function, as observed in the
present study, might have contributed to the cardiovascular
protection and lend support to the emerging concept that
HDL function, such as cholesterol efflux capacity, may be a
better marker of cardiovascular risk than HDL-cholesterol
concentration.
MATERIALS AND METHODS
Characteristics of study subjects and blood collection
Blood was sampled from patients with moderate-to-severe
chronic plaque-type psoriasis and healthy volunteers after obtaining
written informed consent, according to a protocol approved by the
Institutional Review Board of the Medical University of Graz (Nr.: 21-
523 ex 09/10) in adherence to the Helsinki guidelines. The clinical
characteristics and medical history of study subjects are given in
Table 1 and Supplementary Table S1 online. The current investigation
is based on the re-analysis of the pre-treatment serum available from
10 patients of a previous report (Holzer et al., 2012) and 5 newly
enrolled patients and newly sampled blood after anti-psoriatic
treatment in all patients. At the time of the after-treatment
investigation, the patients continued to be on or had completed
treatment. The primary treatment modalities included UVB-311nm
phototherapy (n¼ 3), oral psoralen plus UVA photochemotherapy
(n¼ 1), adalimumab (n¼ 1), etanercept (n¼ 2), ustekinumab (n¼ 2),
methotrexat (n¼ 2), cyclosporin and fumaric acid (n¼ 1), S1P1
agonist (n¼ 1), and topical dithranol (n¼ 2). Additional topical
treatment with calcipotriol (n¼ 7), tacalcitol (n¼ 1), dithranol
(n¼ 3), and/or steroids (n¼ 11) was given in 12 of the 15 patients.
A list with concise information about treatment of individuals can be
found in Supplementary Table S2 online. The time from baseline to
after anti-psoriatic treatment investigation of lipoprotein levels and
functions was 76 weeks (SD±14.7).
Isolation of HDL
Serum density was adjusted with potassium bromide (Sigma, Vienna,
Austria) to 1.24 g ml 1 and a two-step density gradient was generated
in centrifuge tubes (16 76 mm, Beckman Instruments, Krefeld,
Germany) by layering the density-adjusted plasma (1.24 g ml 1)
underneath a KBr-PBS (phosphate-buffered saline)-density solu-
tion (1.063 g ml 1; Holzer et al., 2012). Tubes were sealed and
centrifuged at 90.000 r.p.m. for 4 hours in a 90Ti fixed angle rotor
(Beckman Instruments). After centrifugation, the HDL-containing
band was collected, desalted via PD10 columns (GE Healthcare,
Vienna, Austria), and immediately used for experiments or stored at
 70 1C.
Determination of plasma and HDL lipid composition
Levels of total cholesterol and phospholipids (Diasys, Holzheim,
Germany) were measured enzymatically. LDL-cholesterol was calcu-
lated according to the Friedewald equation using HDL-cholesterol
values measured in the supernatant of the phosphotungstic acid/
MgCl2 precipitation.
Cholesterol efflux capability of HDL
RAW264.7 macrophages (7 106 cells per well), maintained in
DMEM (Dulbecco’s modified Eagle’s medium) with 10% fetal bovine
serum (FBS), were plated in 48-well plates and grown overnight. Cells
were labeled for 24 hours with [3H]cholesterol (1mCi ml 1) in
medium containing 5% FBS, 50mg ml 1 aggregated LDL protein,
and the LXR agonist TO-901317 (2mmol l 1). After labeling, cells
were rinsed and equilibrated in serum-free media containing 0.2%
bovine serum albumin for 2 hours. To determine [3H]cholesterol
efflux, cells were incubated with 50mg ml 1 HDL protein for 3 hours
at 37 1C. Later, the supernatant was collected and used for liquid
scintillation counting.
THP-1 macrophages were maintained and plated in RPMI 1640
with 10% FBS. Cholesterol efflux experiments were performed in
serum-free medium without LXR stimulation as described above.
Cholesterol efflux capability of apoB-depleted serum
ApoB-depleted serum was prepared by addition of 40ml polyethy-
lenglycol (20% in 200 mmol l 1 Glycine buffer) to 100ml serum with
gentle mixing. Serum was incubated at room temperature for
20 minutes and the supernatant recovered after centrifugation
(10,000 r.p.m., 20 minutes, 4 1C). RAW 264.7 macrophages were
plated with DMEM containing 10% FBS in 48-well plates, cultured
for 24 hours, and loaded with 1mCi ml 1 radiolabeled [3H]choles-
terol (Perkin Elmer, Boston, MA) in serum-containing media for
24 hours. The day after labeling, the cells were washed and
stimulated with 0.3 mmol l 1 8-(4-chlorophenylthio)-cyclic AMP
(Sigma, Darmstadt, Germany) in serum-free media for 6 hours to
upregulate ABCA1 as described (Holzer et al., 2011a, b).
Subsequently, cells were washed and efflux measured towards
2.8% apoB–depleted serum in serum-free media for 4 hours. All steps
were performed in the presence 2mg ml 1 of the acyl coenzyme
A:cholesterol acyltransferase inhibitor Sandoz 58-035 (Sigma,
Darmstadt, Germany).
Paraoxonase activity assay
Ca2þ -dependent paraoxonase activity was determined with a photo-
metric assay using phenylacetate as the substrate as described (Holzer
et al., 2012). HDL (5mg protein) was added to 200ml buffer
containing 100 mmol l 1 Tris, 2 mmol l 1 CaCl2 (pH 8.0), and
paraoxon (1 mmol l 1). The rate of hydrolysis of paraoxon was
monitored by the increase of absorbance at 405 nm, and readings
were taken every 150 seconds at room temperature to generate a
kinetic plot. The slope from the kinetic chart was used to determine
DAb270 nm min
 1. Enzymatic activity was calculated with the
Beer–Lambert Law from the molar extinction coefficient of
17,100 l mol 1 cm 1. PON activities were expressed as mmol
4-nitrophenol formed per minute per mg HDL protein.
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Lp-PLA2 activity assay
Lp-PLA2 activity was measured with a commercially available photo-
metric assay (Cayman Europe, Talinn, Estonia) using 2-thio PAF as
substrate as described (Holzer et al., 2012).
PLTP, CETP, LCAT, and serum lipase activity assays
Commercial available kits were used to assess PLTP (Eubio, Vienna,
Austria), CETP (Eubio), LCAT (Merck, Darmstadt, Germany), and
serum lipase activity (Cayman Europe) in sera according to the
manufacturer’s instructions. Activities of CETP and PLTP are expres-
sed as pmol per minute per ml serum. As LCAT activity is measured as
the ratio between wavelengths (470 nm/390 nm), we present activity
values as relative index for easier interpretation, where one represents
the mean activity of psoriasis patients at baseline.
Determination of the anti-oxidative capacity of HDL
The anti-oxidative activity of HDL was determined as previously des-
cribed with modifications (Holzer et al., 2012). Briefly, 7.5mg HDL
protein was placed in a 384-well and 15ml of 50mmol l 1 DHR
reagent containing 1 mmol l 1 2,2’-azobis-2-methyl-propanimid-
amide-dihydrochloride was added. Oxidation of DHR leads to an
increase in fluorescence at 538 nm which was monitored over
time on a microplate reader (XMark, Bio-Rad, Hercules, CA).
Inhibition of DHR oxidation by HDL is expressed as % of oxidation
of DHR in absence of HDL.
HDL particle size analysis
Pooled fraction of HDL (5mg protein per lane) from psoriasis patients
at baseline and after therapy were separated by gradient gel electro-
phoresis (4–16% NativePage; Life Technologies, Vienna, Austria)
under nonreducing and nondenaturing conditions.
Gels were run for 120 minutes at constant voltage of 150 V, in
NativePage running buffer (Life Technologies). Afterwards, gels were
fixed with 25% isopropanol/10% acetic acid for 10 minutes and
stained overnight with Coomassie Brilliant Blue G-250 (Thermo
Scientific, Rockford, IL). To determine the size distribution of isolated
HDL, an image of the gel was analyzed with ImageJ software (NIH,
Bethesda, MD). Intensity blots of individual samples were obtained
and compared with a high molecular weight marker (NativeMark,
Life Technologies), containing bovine serum albumin (7.1 nm), lactate
dehydrogenase (8.2 nm), B-phycoerythrin (10.5 nm, apoferritin band
1 (12.2 nm) and apoferritin band 2 (18.0 nm), to estimate the size of
HDL.
Statistical analysis
Statistical analyses were performed with non-parametric tests due to
the small sample size. Differences in plasma and HDL parameters
between control subjects and psoriasis patients were analyzed with
the Kruskal–Wallis test, while differences between psoriasis patients
before and after therapy were tested with the Wilcoxon signed rank
test for paired observations. All correlations between compositional
and functional data were determined with the use of Spearman
product–moment estimates. Significance was accepted at *Po0.05,
**Po0.01, and ***Po0.01. Statistical analyses were performed with
PASW Statistics Version 19 (IBM, Armonk, NY).
Our study (n¼ 15 vs n¼ 15) provided 490% power to detect a
10% difference in cholesterol efflux capability of HDL based on our
hypothesis that we would observe differences similar to those
between healthy subjects and psoriasis patients as described in our
previous study (Holzer et al., 2012).
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